Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kezar Life Sciences, Inc. - Common Stock (NQ:KZR)

6.270 +0.050 (+0.80%)
Streaming Delayed Price Updated: 12:56 PM EST, Feb 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Kezar Life Sciences, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
Via ACCESSWIRE
News headline image
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as Chief Executive Officer
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences and Everest Medicines Enter into an Agreement to Develop and Commercialize Zetomipzomib for Lupus Nephritis and other Potential Indications in Greater China, South Korea and Southeast Asia
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences to Participate in Three Upcoming Investor Conferences
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences
Via Business Wire
News headline image
Kezar Life Sciences to Participate in the Jefferies Healthcare Conference
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences Reports First Quarter 2023 Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences Reports Fourth Quarter and Year End 2022 Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences to Change Virtual R&D Day Date to March 15, 2023
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences to Host Virtual R&D Day on March 22, 2023
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at the American College of Rheumatology Convergence 2022
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences to Participate in Two Upcoming Investor Conferences
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at ASN’s Kidney Week 2022 Annual Meeting
From Kezar Life Sciences, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.